苯肾上腺素杂质 | 939-38-8

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 苯肾上腺素杂质
• 中文别名: 苯甲醇,3-羟基-a-[(甲基氨基)甲基]-,盐酸(1:1),(aS)-
• 英文名称: (+)-Phenylephrine hydrochloride
• 英文别名: L-phenylephrine hydrochloride；(S)-Phenylephrine Hydrochloride；3-[(1S)-1-hydroxy-2-(methylamino)ethyl]phenol;hydrochloride
• CAS: 939-38-8
• 化学式: C₉H₁₃NO₂*ClH
• 分子量: 203.669
• InChiKey: OCYSGIYOVXAGKQ-SBSPUUFOSA-N

物化性质

• 熔点：
  138 - 143°C
• 溶解度：
  DMSO（微溶）、乙醇（微溶）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  1.07
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.5
• 氢给体数：
  4
• 氢受体数：
  3

安全信息

• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  苯肾上腺素杂质 在 氨 作用下， 以 水 为溶剂， 以94.9%的产率得到L-去氧肾上腺素
  参考文献：
  名称：

  PROCESS FOR RESOLUTION OF 1-(3-HYDROXYPHENYL)-2-METHYLAMINO ETHANOL

  摘要：

  将该化合物分辨到其活性异构体(R)-1-(3-羟基苯基)-2-甲氨基乙醇，使用(R)-萘普生作为分辨剂。

  公开号：

  US20120108848A1
• 作为产物：
  描述：

  1-(3-羟基苯基)-2-(甲氨基)乙酮盐酸盐 在 [(S)-Xyl-P-Phos RuCl₂ (S)-DAIPEN] 氢氧化钾 、 氢气 、 盐酸 作用下， 以 水 、 异丙醇 、 乙醇 为溶剂， 20.0~70.0 ℃ 、3.3 MPa 条件下， 反应 2.75h， 以80%的产率得到苯肾上腺素杂质
  参考文献：
  名称：

  WO2008/77560

  摘要：

  公开号：

文献信息

• 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
  申请人：American Home Products Corporation

  公开号：US04681940A1

  公开（公告）日：1987-07-21

  There are disclosed compounds of the formula ##STR1## wherein X is N or CR.sup.2 Y is O, S, NR.sup.2, CHR.sup.2 or C(R.sup.2).sub.2 when n=0, or N or CR.sup.2 when n=1; p is 0-3; R.sup.1 is ##STR2## R.sup.2 is hydrogen or lower alkyl; R.sup.3 is hydrogen, lower alkyl, phenyl, thienyl, furyl, pyridyl, ##STR3## --C(R.sup.4).sub.3 or --(CH.sub.2).sub.p COOR.sup.2 ; R.sup.4 is halo; Z is O or S; and the pharmaceutically acceptable salts thereof, and their use in the treatment of luekotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

  已公开的化合物的化学式为##STR1##其中X是N或CR.sup.2，Y是O、S、NR.sup.2、CHR.sup.2或C(R.sup.2).sub.2（当n=0时），或N或CR.sup.2（当n=1时）；p为0-3；R.sup.1是##STR2##R.sup.2是氢或低碳烷基；R.sup.3是氢、低碳烷基、苯基、噻吩基、呋喃基、吡啶基、##STR3##--C(R.sup.4).sub.3或--(CH.sub.2).sub.p COOR.sup.2；R.sup.4是卤素；Z是O或S；以及其药用盐，以及它们在治疗白三烯介导的鼻支气管阻塞症状，如过敏性鼻炎、过敏性支气管哮喘等，牛皮癣、溃疡性结肠炎、类风湿关节炎以及其他即时过敏反应中的用途。
• 5-Phenyl-2-oxazole derivatives as anti-inflammatory/antiallergic agents
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0226342A1

  公开（公告）日：1987-06-24

  There are disclosed compounds of formula wherein X is N or CR2; Y is O, S, NR2, CHR2 or C(R2)2 when n = 0 or N or CR2 when n is 1; p is 0 to 3, providing that when p is 0, X is N; R' is R2 is hydrogen or lower alkyl; R3 is hydrogen, lower alkyl, phenyl, thienyl, furyl, pyridyl, C(R4)3 or -(CH2)gCOOR2; R4 is halo; X is 0 or S and q is 0 to 3; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

  公开了如下式子的化合物 其中 X 是 N 或 CR2； 当 n = 0 时，Y 是 O、S、NR2、CHR2 或 C(R2)2；当 n 为 1 时，Y 是 N 或 CR2； p 为 0 至 3，当 p 为 0 时，X 为 N； R' 是 R2 是氢或低级烷基 R3 是氢、低级烷基、苯基、噻吩基、呋喃基、吡啶基、 C(R4)3或-(CH2)gCOOR2； R4 是卤代；X 是 0 或 S，q 是 0 至 3； 及其药学上可接受的盐，以及它们在治疗白三烯介导的鼻-支气管阻塞性气道疾病（如过敏性鼻炎、过敏性支气管哮喘等）、银屑病、溃疡性结肠炎、类风湿性关节炎以及其他即时超敏反应中的用途。
• Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
  申请人：Giordano A. John

  公开号：US20060148837A1

  公开（公告）日：2006-07-06

  The present invention relates to compositions comprising an antitussive, a decongestant and an expectorant, and in a specific embodiment comprising hydrocodone, phenylephrine hydrochloride and guaifenesin, wherein the composition may be substantially free of added sugar and added alcohol, and methods for using these compositions for the treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.

  本发明涉及包含止咳剂、减充血剂和祛痰剂的组合物，在一个具体的实施方案中，包含氢可酮、盐酸苯肾上腺素和愈创木酚，其中组合物可以基本上不添加糖和添加酒精，以及使用这些组合物治疗例如但不限于咳嗽、打喷嚏、鼻出血和/或鼻阻塞患者的方法。
• Compositions and methods of making sustained release liquid formulations
  申请人：Tengler Mark

  公开号：US20060193877A1

  公开（公告）日：2006-08-31

  The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.

  本发明包括用于在货架稳定液体制剂中控制释放活性剂的组合物和方法，具体方法是：混合一种或多种包含一种或多种活性剂的控释微珠，制备密度达到或接近一种或多种包含触变剂的微珠的密度的致密触变溶液、水和一种或多种防腐剂，在减少气泡形成的条件下，将微珠和触变溶液在没有刮板的混合器中混合。
• Phenylephrine derivatives as leukotriene D4 antagonists
  作者：John H. Musser、Dennis M. Kubrak、Reinhold H. W. Bender、Anthony F. Kreft、Susan T. Nielsen、Allan M. Lefer、Joseph Chang、Alan J. Lewis、James M. Hand

  DOI：10.1021/jm00394a026

  日期：1987.11

  Two series of phenylephrine derivatives were prepared and tested as inhibitors of leukotriene D4 (LTD4) induced and ovalbumin-induced bronchospasm in the guinea pig. The most potent compound of the urea series, (R)-N,N-diethyl-N-[2-hydroxy-2-[3-(2-quinolinylmethoxy)phenyl]ethyl]-N- methylurea (3, Wy-47,120), was orally active with ED50's of 56 mg/kg vs. LTD4 and 55 mg/kg vs. ovalbumin. When tested as an antagonist of LTD4-induced contraction of isolated guinea pig tracheal strips, 3 was a competitive inhibitor with a p kappa B value of 5.22. In the second series, (R)-3-methyl-5-[3-(2-quinolinylmethoxy)phenyl]-2-oxazolidinone (26, Wy-47,674) had oral ED50's of 36 mg/kg against LTD4 and 95 mg/kg against ovalbumin. Compound 26 selectively antagonized contractile responses of guinea pig trachea evoked by LTD4 (p kappa B = 6.09). In the cat coronary artery, 3 dilated the preparation and blocked the coronary constrictor effect of LTD4. Compound 3 (0.13 mg/kg, iv) also preserved myocardial integrity in rats 48 h after coronary artery ligation. When tested in the rat alcohol-induced gastric lesion model, 3 and 26 manifested a dose-dependent mucosal protection against ethanol.